BlackRock Institutional Trust’s Heron Therapeutics HRTX Stock Holding History

BlackRock Institutional Trust’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$10.9M	Buy	831,324 +748	+0.1%	+$11.7K	﹤0.01%	2347
2016 Q3	$14.3M	Buy	830,576 +79,227	+11%	+$1.47M	﹤0.01%	2113
2016 Q2	$13.6M	Buy	751,349 +37,108	+5%	+$724K	﹤0.01%	2100
2016 Q1	$13.6M	Buy	714,241 +9,979	+1%	+$197K	﹤0.01%	2070
2015 Q4	$18.8M	Buy	704,262 +48,848	+7%	+$1.31M	﹤0.01%	1912
2015 Q3	$16M	Buy	655,414 +170,638	+35%	+$5.69M	﹤0.01%	1986
2015 Q2	$15.1M	Buy	484,776 +215,701	+80%	+$4.06M	﹤0.01%	2112
2015 Q1	$3.92M	Buy	269,075 +51,736	+24%	+$583K	﹤0.01%	2834
2014 Q4	$2.19M	Sell	217,339 -2,828	-1%	-$23.1K	﹤0.01%	3062
2014 Q3	$1.83M	Buy	220,167 +21,979	+11%	+$205K	﹤0.01%	3112
2014 Q2	$2.44M	Buy	+198,188	New	+$2.37M	﹤0.01%	3100

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

HCMT

Highland Capital Management (Texas) Dallas, Texas $39M AUM

BlackRock Institutional Trust's HRTX Position: Q4 2016 in Review

BlackRock Institutional Trust increased its Heron Therapeutics (HRTX) stake by 0.09% in Q4 2016, buying an estimated $11.7K and bringing the position to 831,324 shares worth $10.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2347.

BlackRock Institutional Trust first reported a position in HRTX in Q2 2014 and has held it in 11 quarters since. The position peaked at $18.8M in Q4 2015. 99 funds tracked by Wall St. Rank hold HRTX as of Q4 2016.

BlackRock Institutional Trust held 831,324 shares of Heron Therapeutics worth $10.9M as of Q4 2016.
BlackRock Institutional Trust bought 748 Heron Therapeutics shares in Q4 2016, an estimated $11.7K.
Heron Therapeutics made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #2347 holding.
BlackRock Institutional Trust first reported a position in Heron Therapeutics in Q2 2014 and has held it in 11 quarters since.
BlackRock Institutional Trust's Heron Therapeutics position peaked at $18.8M in Q4 2015.
99 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.